Skip to main content

Table 1 Correlation between nuclear TIF1γ, cytoplasmic TGFβ1and SMAD4 expression with the clinico-pathologic parameters of breast cancer

From: TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients

Variable TIF1γ low TIF1γ high Pa TGFβ1 low TGFβ1 high Pa SMAD4 low SMAD4 high Pa
No. (%) No. (%)   No. (%) No. (%)   No. (%) No. (%)
143 (64.1) 80 (35.9)   142 (69.6) 62 (30.4)   70 (40.5) 103 (59.5)
Age (Yr) -Mean (± SD) 59.4(±12) 55.9(±13) 0.048b 57.6(±12) 59.3(±14) 0.37b 56.5(±12) 57.1 (±12) 0.74b
Age groups - ≤50y 37 (26) 35 (44) 0.006 44 (31) 21 (34) 0.68 22 (31) 38 (37) 0.46
- >50y 106 (74) 45 (56) 98 (69) 41 (66) 48 (69) 65 (63)
Side -Right 68 (48) 37 (46) 0.85 62 (44) 28 (45) 0.84 30 (43) 51 (49) 0.39
-Left 75 (52) 43 (54) 80 (56) 34 (55) 40 (57) 52 (51)
T. size - ≤2 cm 80 (56) 35 (44) 0.08 73 (51) 30 (48) 0.69 31 (44) 51 (49) 0.49
- >2 cm 63 (44) 45 (56) 69 (49) 32 (52) 39 (56) 52 (51)
LN met -Negative 85 (59) 41 (51) 0.24 79 (56) 35 (57) 0.91 36 (51) 55 (53) 0.79
-Positive 58 (41) 39 (49) 63 (44) 27 (44) 34 (49) 48 (47)
SBR grade -Gr 1 39 (27) 6 (7) <0.001 30 (21) 11 (18) 0.82 5 (7) 26 (25) 0.004
-Gr 2 72 (50) 30 (38) 63 (44) 30 (48) 35 (50) 50 (49)
-Gr 3 32 (23) 44 (55) 49 (35) 21 (34) 30 (43) 27 (26)
ER status -Negative 13 (9) 15 (19) 0.035 24 (17) 6 (10) 0.17 13 (19) 7 (7) 0.02
-Positive 129 (91) 64 (81) 116 (83) 56 (90) 56 (81) 95 (93)
PR status -Negative 28 (20) 22 (28) 0.18 38 (27) 11 (18) 0.14 18 (26) 21 (21) 0.40
-Positive 113 (80) 57 (72) 101 (73) 51 (82) 51 (74) 81 (79)
Her 2 status -Negative 126 (91) 69 (87) 0.35 125 (91) 54 (89) 0.66 60 (90) 90 (89) 0.93
-Over-expressed 12 (9) 10 (13) 13 (9) 7 (11) 7 (10) 11 (11)
Breast cancer subtype -Luminal 127 (91) 64 (81) 0.12c 114 (83) 55 (90) 0.31c 54 (81) 94 (93) 0.05c
-Her2 rich 2 (1) 3 (4) 4 (3) 2 (3) 2 (3) 1 (1)
-Basal 11 (8) 12 (15) 20 (14) 4 (7) 11 (16) 6 (6)
(Neo)/ Adjuv. Hormonal ttt -Tamoxifen 101 (89) 54 (87) 0.89c 95 (92) 44 (83) 0.20c 48 (89) 75 (94) 0.48c
-AI 4 (4) 3 (5) 3 (3) 2 (4) 1 (2) 1 (1)
-Tamoxifen + AI 8 (7) 5 (8) 5 (5) 7 (13) 5 (9) 4 (5)
(Neo)/ Adjuv. chemotherapy -Anthra. 52 (85) 40 (82) 0.61 58 (76) 25 (83) 0.59 34 (74) 44 (80) 0.48c
only 9 (15) 9 (18)   16 (21) 5 (17) c 11 (24) 11 (20)
-Anthra. +        1 (2) 0 (0)
Taxane 0 (0) 0 (0)   2 (3) 0 (0)    
-Others         
  1. aCorrelations tested by Pearson’s Chi square test (2sided) unless otherwise specified
  2. b Difference between means by Student’s T test
  3. c Fisher’s exact test